

# S Percy Ivy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1315450/publications.pdf>

Version: 2024-02-01

27  
papers

2,782  
citations

471371

17  
h-index

552653

26  
g-index

27  
all docs

27  
docs citations

27  
times ranked

5558  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. <i>Journal of Clinical Oncology</i> , 2022, 40, 1949-1957.	0.8	4
2	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	3.0	17
3	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , 2021, 39, 38-53.e7.	7.7	65
4	Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. <i>Oncologist</i> , 2021, 26, e1883-e1886.	1.9	19
5	Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 189, 113464.	1.4	4
6	Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 535-545.	1.1	3
7	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 771-785.	1.9	9
8	Technology Applications: Use of Digital Health Technology to Enable Drug Development. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	1.0	14
9	Drug development and registration: Challenges and opportunities in ovarian cancer. <i>Cancer</i> , 2017, 123, 2597-2599.	2.0	0
10	The <i>HRD</i> Decision<i>â€œ</i>Which PARP Inhibitor to Use for Whom and When. <i>Clinical Cancer Research</i> , 2017, 23, 7155-7157.	3.2	22
11	Whence High-Grade Serous Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 443-448.	1.8	15
12	Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncologyâ€™s Friends of Cancer Research Minimum Age Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3781-3787.	0.8	69
13	The â€œPushmi-Pullyuâ€™ of DNA REPAIR: Clinical Synthetic Lethality. <i>Trends in Cancer</i> , 2016, 2, 646-656.	3.8	18
14	Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 597-611.	1.9	44
15	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	7
16	Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Programâ€™s Sponsored Single-Agent Phase I Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 110-116.	0.8	27
17	CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 123.	1.3	21
18	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. <i>Gynecologic Oncology</i> , 2015, 137, 216-222.	0.6	65

#	ARTICLE	IF	CITATIONS
19	Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 445-464.	12.5	1,053
20	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. <i>Oncotarget</i> , 2015, 6, 19316-19327.	0.8	13
21	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1207-1214.	5.1	523
22	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014, 50, 2050-2056.	1.3	63
23	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	1.2	50
24	Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1726-1736.	3.2	152
25	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1764-1769.	3.2	143
26	An overview of small-molecule inhibitors of VEGFR signaling. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 569-579.	12.5	305
27	Molecular Mechanism of Antifolate Transport-Deficiency in a Methotrexate-Resistant MOLT-3 Human Leukemia Cell Line. <i>Blood</i> , 1997, 89, 2494-2499.	0.6	57